Archived explainer. For the current picture see today's TEVA page.
TEVA PHARMACEUTICAL ADR (TEVA) is up +9.60% in the latest session. Our newswire has captured 15 stories on TEVA across 9 sources in the last 36 hours, with AI sentiment reading bullish (avg 60/100).
TEVA stock rose 9.60% to $34.71 in the latest session as the company delivered better-than-expected revenue and raised its full-year outlook for key innovative brands. The move followed the release of Q2 2026 earnings results that highlighted strong performance from AUSTEDO, AJOVY, and UZEDY, which offset a decline in generic revenue and an earnings miss driven by acquisition-related expenses. The company also announced plans to transition to a direct listing on the NYSE, effective September 14, 2026, which added to investor optimism.
Teva reported second-quarter revenue of $4.142 billion, exceeding the $4.047 billion estimate. While adjusted earnings per share of $0.02 fell short of the $0.25 forecast, the company raised its 2026 revenue guidance for its innovative brands. AUSTEDO, AJOVY, and UZEDY are now expected to generate $2.45 billion to $2.6 billion, $850 million to $870 million, and $77 million in net sales, respectively. UZEDY alone saw record Q2 net sales of $77 million, a 43% year-over-year increase. Teva also raised its full-year revenue guidance to a range of $16.5 billion to $16.85 billion. Despite lowering its adjusted EPS guidance to $1.91 to $2.11, the company emphasized long-term growth through its innovative portfolio and structural changes.
TEVA’s stock has traded between $14.99 and $37.34 over the past 52 weeks. The stock’s beta of 0.86 suggests it is less volatile than the broader market. Intraday volume was unusually high, with unusual options activity including three notable prints. Call premiums totaled $495,000, while put premiums reached $630,000, with the largest single print at $630,000. Recent insider transactions show six sales over the past 90 days, totaling $11.6 million, with no buys reported.
Teva has not scheduled earnings for the near term, but investors will closely monitor the company’s progress toward its revised revenue guidance and the impact of its direct listing on the NYSE beginning September 14, 2026. Coverage breadth is also a key factor as the market digests the updated outlook for its innovative brands.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Teva Pharmaceutical Industries Limited (($TEVA)) has held its Q2 earnings call. Read on for the main highlights of the call. Teva Pharmaceutical Industries struck a...
Teva (TEVA) Q2 2026 earnings call recap: raised revenue guidance on AUSTEDO/AJOVY/UZEDY, Emalex IPR&D hit, IRA & inventory risks—read now.
Teva Pharmaceutical Industries Limited (TEVA) Q2 2026 Earnings Call July 29, 2026 8:00 AM EDTCompany ParticipantsChristopher Stevo - Senior Vice President...
Teva delivered strong Q2 2026 results driven by exceptional growth from key innovative brands AUSTEDO, AJOVY, and UZEDY, even as generic revenues declined. The company raised its revenue outlook for these flagship drugs and remains focused on its growth strategy through innovation, portfolio modernization, and cost efficiency. Read on for a data-driven breakdown of segment performance, financial health, and what's driving the next phase for TEVA.
Teva (NYSE:TEVA) reported second-quarter revenue above expectations as strong growth from AUSTEDO, AJOVY and UZEDY offset an earnings miss caused by acquisition-related expenses, while the company raised its full-year revenue outlook.
Why is Teva Pharma stock surging today?
Teva Pharmaceutical (TEVA) stock gains after the company announces plans to seek a direct listing in the U.S. with its Q2 2026 financials. Read more here.
More on TEVA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier TEVA move explainers: 2026-07-30 · 2026-07-29